115 related articles for article (PubMed ID: 25655921)
21. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
Rivera GK; Zhou Y; Hancock ML; Gajjar A; Rubnitz J; Ribeiro RC; Sandlund JT; Hudson M; Relling M; Evans WE; Pui CH
Cancer; 2005 Jan; 103(2):368-76. PubMed ID: 15599932
[TBL] [Abstract][Full Text] [Related]
22. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
Marshall GM; Dalla Pozza L; Sutton R; Ng A; de Groot-Kruseman HA; van der Velden VH; Venn NC; van den Berg H; de Bont ES; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJ; Bierings MB; van der Schoot E; van Dongen J; Law T; Cross S; Mueller H; de Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R
Leukemia; 2013 Jul; 27(7):1497-503. PubMed ID: 23407458
[TBL] [Abstract][Full Text] [Related]
23. [High risk acute lymphoblastic leukaemia in children. Preliminary report after introducing a new version of New York (1997) protocol adjusted to the age of the patients. Report of the Polish Paediatric Leukaemia/Lymphoma Study Group].
Skoczen S; Klus K; Armata J; Kowalczyk J; Wisniewska-Slusarz H; Kolecki P; Derwich K; Matysiak M; Krauze A; Rokicka-Milewska R; Pawelec K; Boguslawska-Jaworska J; Juszczak K; Pisarek J; Sońta-Jakimczyk D; Tomaszewska R; Łuszczynska A; Wysocki M; Styczyński J
Med Wieku Rozwoj; 2000; 4(1 Suppl 2):23-32. PubMed ID: 12021459
[TBL] [Abstract][Full Text] [Related]
24. Implementation of an intensive risk-stratified treatment protocol for children and adolescents with acute lymphoblastic leukemia in Lebanon.
Muwakkit S; Al-Aridi C; Samra A; Saab R; Mahfouz RA; Farra C; Jeha S; Abboud MR
Am J Hematol; 2012 Jul; 87(7):678-83. PubMed ID: 22565284
[TBL] [Abstract][Full Text] [Related]
25. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
26. [Clinical features and prognosis of children with lymphoblastic lymphoma].
Jin L; Zhang R; Huang S; Yang J; Duan YL; Zhang YH
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):138-42. PubMed ID: 22780934
[TBL] [Abstract][Full Text] [Related]
27. High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL).
Jabbour E; Koscielny S; Sebban C; Peslin N; Patte C; Gargi T; Biron P; Fermé C; Bourhis JH; Vantelon JM; Arnaud P; Ribrag V
Leukemia; 2006 May; 20(5):814-9. PubMed ID: 16511514
[TBL] [Abstract][Full Text] [Related]
28. Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia.
Kumar P; Kun LE; Hustu HO; Mulhern RK; Hancock ML; Coffey D; Rivera GK
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):477-83. PubMed ID: 7852109
[TBL] [Abstract][Full Text] [Related]
29. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.
Nachman JB; Sather HN; Sensel MG; Trigg ME; Cherlow JM; Lukens JN; Wolff L; Uckun FM; Gaynon PS
N Engl J Med; 1998 Jun; 338(23):1663-71. PubMed ID: 9614257
[TBL] [Abstract][Full Text] [Related]
30. Acute lymphoblastic leukaemia therapy in Poland. A report from the Polish Children's Leukaemia/Lymphoma Study Group.
Radwańska U; Michalewska D; Armata J; Balwierz W; Bogusławska-Jaworska J; Cyklis R; Derulska D; Kołecki P; Lastowska M; Newecka-Samól T
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(2):199-210. PubMed ID: 2475398
[TBL] [Abstract][Full Text] [Related]
31. Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962.
Avramis IA; Panosyan EH; Dorey F; Holcenberg JS; Avramis VI;
Clin Cancer Res; 2006 Dec; 12(23):6978-84. PubMed ID: 17145817
[TBL] [Abstract][Full Text] [Related]
32. [Lineage switch - conversion of acute lymphoblastic leukaemia to acute myeloid leukaemia in 4 years old girl].
Szpecht D; Derwich K; Wachowiak J; Konatkowska B; Dworacki G
Med Wieku Rozwoj; 2008; 12(4 Pt 2):1041-4. PubMed ID: 19531823
[TBL] [Abstract][Full Text] [Related]
33. Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia.
Paganin M; Fabbri G; Conter V; Barisone E; Polato K; Cazzaniga G; Giraldi E; Fagioli F; Aricò M; Valsecchi MG; Basso G
J Clin Oncol; 2014 Nov; 32(31):3553-8. PubMed ID: 25287825
[TBL] [Abstract][Full Text] [Related]
34. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
[TBL] [Abstract][Full Text] [Related]
35. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
37. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
38. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
[TBL] [Abstract][Full Text] [Related]
39. NOTCH1 mutations are associated with favourable long-term prognosis in paediatric T-cell acute lymphoblastic leukaemia: a retrospective study of patients treated on BCH-2003 and CCLG-2008 protocol in China.
Gao C; Liu SG; Zhang RD; Li WJ; Zhao XX; Cui L; Wu MY; Zheng HY; Li ZG
Br J Haematol; 2014 Jul; 166(2):221-8. PubMed ID: 24690100
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
Coustan-Smith E; Gajjar A; Hijiya N; Razzouk BI; Ribeiro RC; Rivera GK; Rubnitz JE; Sandlund JT; Andreansky M; Hancock ML; Pui CH; Campana D
Leukemia; 2004 Mar; 18(3):499-504. PubMed ID: 14981525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]